 |
|
|
|
|
Allied health professionals play a vital role in the care and support of patients. It is critical, therefore, for them to acquire foundational IO knowledge and techniques as it pertains to their role.
SIO’s new Allied Health Program features an innovative and practical program designed specifically with registered nurses and technologists in mind. Program highlights include the history of IO, insights into the most recent advances in care for various cancer types, updates on innovations in interventional techniques to treat cancer patients, a look at immune-oncology and MSK interventions, imaging guidance, technology, and more.
Encourage your allied health professional to attend SIO 2019 alongside you – at no cost.*
*Offer valid with a paid Full Conference Physician Registration, for more information contact info@sio-central.org
Dear SIO members,
As we strategize for the future of Interventional Oncology, we have opportunity to collaborate closely with some of the NCI Cooperative Groups to promote combination treatment concepts and trials. SIO has already made tremendous strides within ECOG-ACRIN, establishing the first Interventional Oncology Working Group and liaising with the relevant GI Working Groups, (Hepatobiliary, CRC, NET, Surgery). In addition, interventional oncologists have been appointed to the NCTN Task Forces for CRC and NET.
We are working next with SWOG, and soliciting volunteers. Your activities will include scheduled calls, attending SWOG meetings and developing/participating in concepts and trials.
For those who are interested, this opportunity and your efforts will bring innovative combination treatment concepts/trials, enhancement of our patients’ care and your leadership in cutting edge interventional oncologic care.
If you are from a SWOG institution and/or you work closely with oncology partners affiliated with SWOG and interested in taking part, please let us know.
The next SWOG meeting will be in San Francisco, April 24-27, 2019.
Best wishes,
Kevin Kim, MD, SIO Cooperative Group Task Force
Yale School of Medicine
Steve Solomon, MD, SIO President
Memorial Sloan Kettering Cancer Center
| Promoted by |
|
|
|
 |
 The field of Interventional Oncology, as well as the continued success of SIO, is dependent on the support of members. SIO membership not only illustrates dedication to the mission of the society, but to the continued growth and success of the field of IO.
If you are planning on attending SIO’s Annual Scientific Meeting this year, you can bundle your SIO 2019 registration with SIO membership and other add-ons and get the most out of your conference registration – for a reduced cost! Bundling your conference registration with membership to the Society of Interventional Oncology also allows you to benefit from access to a global network of IO professionals well beyond 8–11 June.
Visit the SIO website for more information membership renewal and on our new registration packages and other ways to get involved with the only society dedicated to advancing the field of IO.
Journal of Medical Ultrasonics
This is an evaluation of clinical application of ultrasound-guided percutaneous microwave ablation treatment for T1a renal carcinoma. Analysis of the clinical data from 31 patients with T1aN0M0 stage renal carcinoma who underwent ultrasound-guided percutaneous microwave ablation. All of the 31 patients were treated with ablation only once: 96.8% of patients had no local recurrence or distant metastasis after ablation. Complications were found in 9.7% of the patients. Ultrasound-guided percutaneous microwave ablation is a safe and effective micro-invasive therapy for T1a renal cancer patients. READ MORE
Journal of Hepatology
The aim of this study was to assess the impact of DAAs on OS, HCC recurrence and hepatic decompensation. We enrolled prospectively 163 consecutive patients with HCV-related cirrhosis and at first diagnosis of early Barcelona Clinic Liver Cancer (BCLC) 0/A HCC who had achieved a complete radiologic response after curative resection or ablation, subsequently treated with DAAs. DAA-untreated patients from ITA.LI.CA. cohort served as controls. In patients with HCV-related cirrhosis and previous successful treatment of early HCC, DAAs significantly improved OS compared with No DAA treatment. READ MORE |
|
European Radiology
The purpose of this study was to compare utilization and effectiveness of radiofrequency ablation and surgical resection for hepatocellular carcinoma. The 2004–2015 U.S. National Cancer Database was queried for HCC patients treated by RFA and surgical resection. Patients were 1:1 propensity score matched. Duration of hospital stay, unplanned readmission rates and overall survival were compared in the matched cohort via multivariable regression models. RFA for HCC shows substantial variation by geography, socioeconomic factors, liver function and tumor extent. The study concluded that RFA offers superior post-treatment outcomes versus surgical resection and may be an alternative for older patients with cirrhosis and/or small HCC. READ MORE
Journal of Gastroenterology and Hepatology
A 65‐year‐old, chronic alcoholic and smoker man presented with right‐sided upper abdominal pain of 2‐month duration. His routine hematological and blood biochemistry including serum amylase and liver function tests were normal. Computed tomography of abdomen revealed a 4‐cm retroperitoneal mass adjacent to the third part of duodenum compressing the inferior vena cava. Endoscopic ultrasound revealed marked asymmetrical thickening of the IVC wall with luminal narrowing. However, there was no thrombosis, and blood flow could be visualized through the luminal narrowing on color Doppler. READ MORE |
| Cryotherapy is a minimally invasive treatment primarily for kidney, lung, and prostate cancers as well as a palliative treatment for bone pain. It has been used since the 19th Century(see history below), but advancements continue to be made every year. Read more |
|
|
|
|
|
|
Journal of Hematology & Oncology
Immunotherapy has been verified as an effective strategy in multiple cancers, but some problems still exist in actual clinical practice such as frequent primary and adaptive resistance. Recently, a series of studies demonstrated that the vital component of host innate immunity — cGAS-STING pathway might play an important role in anti-cancer immunity. In this review, we highlight the latest understanding of cGAS-STING pathway and the advances of the combination therapy of STING agonist and immunotherapy. READ MORE
Hepatology
Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease in developed countries and its incidence is rapidly increasing. Cirrhosis, and the dreaded complication of hepatocellular carcinoma (HCC), are the major drivers of morbidity and mortality in NASH. Conventional understanding has been that chronic liver damage leads to a cycle of cell death, regeneration and fibrosis during which HCC precursor cells undergo malignant transformation and lead to cancer initiation. READ MORE
Journal of Vascular and Interventional Radiology
A retrospective assessment of 297 patients with biopsy-proven RCC treated with image-guided percutaneous thermal ablation was performed between October 2006 and December 2016. Assessments of adverse events, treatment efficacy, and therapeutic outcomes were performed among RF ablation, cryoablation, and MWA. The 2-year disease-free, metastatic-free and cancer-specific survival rates were tabulated. Estimated glomerular filtration rate was used to assess for treatment related changes in renal function. RF ablation, cryoablation and MWA are equivalent at 2 years for treatment of T1a RCC for therapeutic outcome, stability of renal function and low adverse event rate. READ MORE
Journal of Surgical Oncology
Colorectal liver metastases are not always resectable at the time of diagnosis. An insufficient future liver remnant is a factor excluding patients from curative intent resection. To deal with this issue, two‐stage hepatectomy was introduced approximately 20 years ago. It is a sequential treatment strategy for bilateral CLM, which consists of preoperative chemotherapy, portal vein embolization, and planned first and second liver resections. This study reviews current evidence supporting use of two‐stage hepatectomy. READ MORE |
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063 |
